Wegovy Buoys Novo Nordisk To Highest-Ever Sales

 
• By Elizabeth Cairns
  
Generate a summary of this article
Listen to this article
Beta

But the Danish group is still bedeviled by supply problems, and much is hanging on upcoming cardiovascular outcomes data.  

NovoNordisk

Novo Nordisk A/S is cheerfully setting about destroying its own customer base. Even as the Danish group’s Q3 sales soared by 38% at constant currencies to DKK58.7bn ($8.3bn), its insulin sales contracted, partly because its own Ozempic (semaglutide injection 0.5mg, 1mg, 2mg) means many formerly insulin-dependent diabetes patients no longer need to use the hormone.

Key Takeaways

  • Novo Nordisk reports Q3 sales of $8.3bn and raises its full-year guidance

The company still cannot meet demand for Ozempic and semaglutide’s other incarnation, Wegovy (semaglutide injection 2.4mg) for obesity, however, and...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.